These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38935819)

  • 21. The benefits of neoadjuvant therapy for patients with resectable pancreatic cancer: an updated systematic review and meta-analysis.
    Yang B; Chen K; Liu W; Long D; Wang Y; Liu X; Ma Y; Tian X; Yang Y
    Clin Exp Med; 2023 Nov; 23(7):3159-3169. PubMed ID: 37310659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.
    Ghaneh P; Palmer D; Cicconi S; Jackson R; Halloran CM; Rawcliffe C; Sripadam R; Mukherjee S; Soonawalla Z; Wadsley J; Al-Mukhtar A; Dickson E; Graham J; Jiao L; Wasan HS; Tait IS; Prachalias A; Ross P; Valle JW; O'Reilly DA; Al-Sarireh B; Gwynne S; Ahmed I; Connolly K; Yim KL; Cunningham D; Armstrong T; Archer C; Roberts K; Ma YT; Springfeld C; Tjaden C; Hackert T; Büchler MW; Neoptolemos JP;
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):157-168. PubMed ID: 36521500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials.
    Ghanem I; Lora D; Herradón N; de Velasco G; Carretero-González A; Jiménez-Varas MÁ; Vázquez de Parga P; Feliu J
    ESMO Open; 2022 Jun; 7(3):100485. PubMed ID: 35580504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative efficacy and safety of neoadjuvant radiotherapy for patients with borderline resectable, and locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis protocol.
    Lv W; Wang Q; Hu Q; Wang X; Cao D
    BMJ Open; 2022 Jul; 12(7):e050558. PubMed ID: 35831044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.
    Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T
    Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
    Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
    JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comparative studies by intention-to-treat analysis.
    Unno M; Hata T; Motoi F
    Surg Today; 2019 Apr; 49(4):295-299. PubMed ID: 30877550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.
    Versteijne E; Suker M; Groothuis K; Akkermans-Vogelaar JM; Besselink MG; Bonsing BA; Buijsen J; Busch OR; Creemers GM; van Dam RM; Eskens FALM; Festen S; de Groot JWB; Groot Koerkamp B; de Hingh IH; Homs MYV; van Hooft JE; Kerver ED; Luelmo SAC; Neelis KJ; Nuyttens J; Paardekooper GMRM; Patijn GA; van der Sangen MJC; de Vos-Geelen J; Wilmink JW; Zwinderman AH; Punt CJ; van Eijck CH; van Tienhoven G;
    J Clin Oncol; 2020 Jun; 38(16):1763-1773. PubMed ID: 32105518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant Chemotherapy and Radiation Improves Recurrence-free and Overall Survival in Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
    Kelley JK; Kolbeinsson H; Chandana S; Eastburg B; Frisch A; Parker J; Wright GP; Assifi MM; Chung M
    Am Surg; 2024 Nov; 90(11):2762-2768. PubMed ID: 38676648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy.
    Wijetunga AR; Chua TC; Nahm CB; Pavlakis N; Clarke S; Chan DL; Diakos C; Maloney S; Ashrafi-Zadeh A; Kneebone A; Hruby G; Jamieson NB; Gill A; Mittal A; Samra JS
    Eur J Surg Oncol; 2021 Oct; 47(10):2543-2550. PubMed ID: 33952409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis.
    Chan KKW; Saluja R; Delos Santos K; Lien K; Shah K; Cramarossa G; Zhu X; Wong RKS
    Int J Cancer; 2018 Jul; 143(2):430-437. PubMed ID: 29441562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial.
    Jang JY; Han Y; Lee H; Kim SW; Kwon W; Lee KH; Oh DY; Chie EK; Lee JM; Heo JS; Park JO; Lim DH; Kim SH; Park SJ; Lee WJ; Koh YH; Park JS; Yoon DS; Lee IJ; Choi SH
    Ann Surg; 2018 Aug; 268(2):215-222. PubMed ID: 29462005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis.
    Bradley A; Van Der Meer R
    Sci Rep; 2019 Mar; 9(1):4354. PubMed ID: 30867522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
    Thanikachalam K; Damarla V; Seixas T; Dobrosotskaya I; Wollner I; Kwon D; Winters K; Raoufi M; Li J; Siddiqui F; Khan G
    Am J Clin Oncol; 2020 Jun; 43(6):435-441. PubMed ID: 32251119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognosis of Upfront Surgery for Pancreatic Cancer: A Systematic Review and Meta-Analysis of Prospective Studies.
    Pecorelli N; Licinio AW; Guarneri G; Aleotti F; Crippa S; Reni M; Falconi M; Balzano G
    Front Oncol; 2021; 11():812102. PubMed ID: 35083158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
    Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
    BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy.
    di Sebastiano P; Grottola T; di Mola FF
    Updates Surg; 2016 Sep; 68(3):235-239. PubMed ID: 27629483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy.
    Blair AB; Rosati LM; Rezaee N; Gemenetzis G; Zheng L; Hruban RH; Cameron JL; Weiss MJ; Wolfgang CL; Herman JM; He J
    Surgery; 2018 May; 163(5):1090-1096. PubMed ID: 29395234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
    Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
    Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
    Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.